“Amniotic Membrane Market Report is set to have rapid growth due the rising awareness and the presence of technologically advanced countries in terms of healthcare and medical research at global, regional and national level, influencing the industry trends in each of the sub-segments from 2019 to 2029”, says Visiongain Report

04 September 2019
Pharma

Visiongain has launched a new pharma report Amniotic Membrane Market Forecast 2019-2029: By End Use (ASC, Hospital), By Enzyme (Dehydrated, Cryopreserved), By Application (Ophthalmology, Surgical Wounds), Region and Segment Forecasts

The global Amniotic Membrane market is poised for rapid growth between 2019 and 2029. The growing awareness in the recent past has led to an increase in the number of transplants which has led to a growing demand for these tissue-based products. It has also led to an increase in the number of donations, thus fueling market growth.

The main factors driving the growth of the amniotic membrane market is the increase in the geriatric population combined with the increase in transplantation based on the amniotic membrane at the global level. However, the lack of qualified professionals and the high cost of surgical interventions involving the amniotic membrane slow the growth of the global amniotic membrane market. Furthermore, increasing awareness of the potential benefits of the amniotic membrane between patients and healthcare professionals offers profitable opportunities that promote the market.

Leading companies featured in the report include Alliqua BioMedical, Inc.; Amnio Technology, LLC; Applied Biologics LLC; Human Regenerative Technologies, LLC; DermaSciences; Katena Products, Inc.; MiMedx Group, Inc.; Skye Biologics, Inc.; Amniox Medical, Inc.; and Organogensis, Inc.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Oncology remains the largest disease area in the pharmaceutical business. The oncology market is dominated by big pharma companies and high price labels” says Visiongain report

Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.

10 September 2019

Read

“Anti-Infective Agents market set to grow to $141bn by 2024” says new Visiongain report

The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.

09 September 2019

Read

“Global thyroid gland disorder treatment market is anticipated to grow at a lucrative CAGR of 3.6% and anticipated to reach USD 3.21 Billion by 2029”, says Visiongain report.

Thyroid disease is one of today’s most prevalent hormonal illnesses. Hyperthyroidism, hypothyroidism, and thyroid nodules are the most common thyroid gland disorders.

05 September 2019

Read

“Global somatostatin analogs market is anticipated to grow at a lucrative CAGR of 5.3% and anticipated to reach USD 4.78 Bn by 2029”, says Visiongain report.

Somatostatin was used to diagnose gastrointestinal tract tumors and acromegaly in the clinical environment.

05 September 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever